Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dazhao Mi"'
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 30, Iss , Pp 351-352 (2022)
Externí odkaz:
https://doaj.org/article/724889ef7fb74b7e89ce9835314f6e98
Publikováno v:
Journal of Medicinal Chemistry. 65:15559-15583
B-cell lymphoma 6 (BCL6) is a transcriptional repressor that regulates the differentiation of B lymphocytes and mediates the formation of germinal centers (GCs) by recruiting corepressors through the BTB domain of BCL6. Physiological processes regula
Publikováno v:
European Journal of Medicinal Chemistry. 256:115444
Autor:
Yuzhu Zhang, Jing Chen, Dazhao Mi, Jun Ling, Huachao Li, Peng He, Ning Liu, Qianjun Chen, Yihua Chen, Luqi Huang
Publikováno v:
Cancer Letters. :216195
Autor:
Luzhen Wang, Dazhao Mi, Jinhui Hu, Wenjing Liu, Yi Zhang, Chunyan Wang, Yihua Chen, Ceshi Chen
Publikováno v:
Cancer Letters. 555:216049
Triple-negative breast cancer (TNBC) is one of the most malignant tumors with poor prognosis. Methuosis is a new type of nonapoptotic cell death characterized by the accumulation of cytoplasmic vacuoles. In this study, we synthesized and screened a s
Autor:
Dazhao Mi, Jianping Jin, Wenbo Zhou, Xinyue Wang, Yihua Chen, Mingyao Liu, Haixiang Pei, Qiuhui Duan, Dali Li, Liang Li
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 5, Iss 1, Pp 1-3 (2020)
Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy
Autor:
Dazhao Mi, Peili Wang, Shao Ting, Mingyao Liu, Zhengfang Yi, Yuanjin Zhang, Xin Wang, Haixiang Pei, Weikai Guo, Yihua Chen, Yunqi Li, Yuan He, Isabelle Krimm
Publikováno v:
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, American Chemical Society, 2019, 62 (10), pp.4949-4966. ⟨10.1021/acs.jmedchem.9b00059⟩
Journal of Medicinal Chemistry, American Chemical Society, 2019, 62 (10), pp.4949-4966. ⟨10.1021/acs.jmedchem.9b00059⟩
Pancreatic cancer is one of the most common cancers with an extremely low survival rate. Metastasis, as one of the key reasons of cancer-related death, is found in more than 50% pancreatic cancer patients at diagnosis. Novel therapeutic targets and d